Gene/Cell Therapies: US FDA Clarifies INTERACT, Pre-IND Meeting Timing In FAQ Guidance

New US FDA draft guidance attempts to address sponsor confusion about the different types of regulatory meetings under PDUFA, as well as frequently asked questions on nonclinical testing, CMC, pharm/tox and clinical studies.